Search

Jens Harborth

from San Diego, CA
Age ~60
Get Report
Also known as:
Jens Harboth
Related to:
Hai Viet Vu, 72Lani Thi Nguyen, 68
Connected to:
Cathy A Harborth, 61Daniel T Harborth, 43Bill J Harbottle, 64Ben E Harbour, 76Casey M Harbour, 31Cheryl A Harbour, 77Corey Harbour, 35Dale E Harbour, 55David Harbour, 59Dean T Harbour, 69

Jens Harborth Phones & Addresses

  • San Diego, CA
  • Carlsbad, CA
  • Roxbury, MA
  • Waltham, MA
  • Cambridge, MA
  • 271 Florence Rd, Waltham, MA 02453

Work

Company: Nitto biopharma Apr 2016 Position: Director, research and rnai lead development

Education

School / High School: The University of Göttingen 2003 Specialities: Biochemistry, Biology

Skills

Drug Discovery • Biotechnology • Protein Chemistry • Biochemistry • Antibodies • Cell Biology • Immunoassays • Molecular Biology • Cell • Lifesciences • Clinical Trials • Biopharmaceuticals • Life Sciences • Pharmaceutical Industry • Sop • Gmp • Immunology • Assay Development • Drug Development

Languages

English • German

Industries

Biotechnology

Resumes

Resumes

Jens Harborth Photo 1

Director, Research And Rnai Lead Development

View page
Location:
2342 Lapis Rd, Carlsbad, CA 92009
Industry:
Biotechnology
Work:
Nitto Biopharma
Director, Research and Rnai Lead Development
Nitto Denko
Director, Biology
Eutropics Pharmaceuticals Sep 2013 - Sep 2014
Consultant
Hopedx Llc May 2012 - Sep 2014
Scientific Advisor
Merrimack Jan 2011 - Apr 2012
Investigator
Education:
The University of Göttingen 2003
The University of Göttingen 1991 - 1995
Doctorates, Doctor of Philosophy, Biochemistry, Biology
Skills:
Drug Discovery
Biotechnology
Protein Chemistry
Biochemistry
Antibodies
Cell Biology
Immunoassays
Molecular Biology
Cell
Lifesciences
Clinical Trials
Biopharmaceuticals
Life Sciences
Pharmaceutical Industry
Sop
Gmp
Immunology
Assay Development
Drug Development
Languages:
English
German

Publications

Us Patents

Compositions And Methods For Inhibiting Expression Of Ikk-B Gene

View page
US Patent:
20080108584, May 8, 2008
Filed:
May 21, 2007
Appl. No.:
11/751283
Inventors:
ANTONIN DE FOUGEROLLES - Brookline MA, US
ANDREW SPRAGUE - Haverhill MA, US
JENS HARBORTH - Boston MA, US
MARIA BELVISI - Liverpool, GB
MARK BIRRELL - Essex, GB
ELIZABETH HARDAKER - London, GB
MATTHEW CATLEY - London, GB
International Classification:
A61K 31/7052
A61P 29/00
C07H 21/02
C12N 15/63
C12N 5/00
US Classification:
514044000, 435320100, 435325000, 435455000, 536023100
Abstract:
The invention relates to a doable-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the IKK-B gene, comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the IKK-B gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases, caused by the expression or activation of the IKK-B gene using the pharmaceutical composition; and methods for inhibiting the expression of the IKK-B gene in a cell.

Compositions And Methods For Inhibiting Expression Of Ikk-B Gene

View page
US Patent:
20110112178, May 12, 2011
Filed:
Dec 30, 2010
Appl. No.:
12/982261
Inventors:
Antonin de Fougerolles - Brookline MA, US
Andrew Sprague - Haverhill MA, US
Jens Harborth - Boston MA, US
Maria Gabriela Belvisi - Aigburth, GB
Mark Andrew Birrell - Upminster, GB
Elizabeth Ouise Hardaker - London, GB
Matthew Copeland Catley - London, GB
Assignee:
ALNYLAM PHARMACEUTICALS, INC. - Cambridge MA
International Classification:
A61K 31/713
C07H 21/02
C12N 15/63
C12N 5/00
A61P 29/00
US Classification:
514 44 R, 536 231, 4353201, 435325
Abstract:
The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the IKK-B gene, comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the IKK-B gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression or activation of the IKK-B gene using the pharmaceutical composition; and methods for inhibiting the expression of the IKK-B gene in a cell.

Sirna Structures For High Activity And Reduced Off Target

View page
US Patent:
20220267779, Aug 25, 2022
Filed:
May 3, 2022
Appl. No.:
17/661803
Inventors:
- Osaka, JP
Jens Harborth - San Diego CA, US
Cima Cina - San Diego CA, US
Wenbin Ying - San Diego CA, US
Jane Zheng - San Diego CA, US
Narendra Vaish - Kirkland WA, US
International Classification:
C12N 15/113
Abstract:
This invention provides compounds, compositions and methods for modulating the expression of target genes using RNA interference. RNAi structures and molecules of this invention can be used for modulating or silencing the expression of genes, with high levels of RNAi activity and reduced off target actions. Advantageous structures include siRNAs targeted to any gene having one or more 2′-deoxy nucleotides located in the seed region. The RNA interference molecules can be used in methods for preventing or treating diseases.

Sirna Structures For High Activity And Reduced Off Target

View page
US Patent:
20190323015, Oct 24, 2019
Filed:
Jun 25, 2019
Appl. No.:
16/451757
Inventors:
- Osaka, JP
Jens Harborth - Carlsbad CA, US
Cima Cina - San Diego CA, US
Wenbin Ying - San Diego CA, US
Jane Zheng - Oceanside CA, US
Narendra Vaish - Kirkland WA, US
International Classification:
C12N 15/113
Abstract:
This invention provides compounds, compositions and methods for modulating the expression of target genes using RNA interference. RNAi structures and molecules of this invention can be used for modulating or silencing the expression of genes, with high levels of RNAi activity and reduced off target actions. Advantageous structures include siRNAs targeted to any gene having one or more 2′-deoxy nucleotides located in the seed region. The RNA interference molecules can be used in methods for preventing or treating diseases.

Rna Interference Agents For Gst-Pi Gene Modulation

View page
US Patent:
20180369274, Dec 27, 2018
Filed:
Aug 12, 2018
Appl. No.:
16/101490
Inventors:
- Osaka, JP
Hirokazu Takahashi - Osaka, JP
Erika Terada - Osaka, JP
Jens Harborth - Carlsbad CA, US
Jun Zhang - San Diego CA, US
Mohammad Ahmadian - Carlsbad CA, US
Wenbin Ying - San Diego CA, US
International Classification:
A61K 31/7105
A61P 35/00
Abstract:
This invention provides compounds, compositions and methods for modulating the expression of human GST-π using RNA interference. The RNA interference molecules can be used in methods for preventing or treating diseases such as malignant tumor. Provided are a range of siRNA structures, having one or more of nucleotides being modified or chemically-modified. Advantageous structures include siRNAs with 2′-deoxy nucleotides located in the seed region, as well as other nucleotide modifications.

Rna Interference Therapeutics Against Ebola Virus

View page
US Patent:
20180235995, Aug 23, 2018
Filed:
Feb 18, 2016
Appl. No.:
15/551270
Inventors:
Wenbin Ying - , US
- Osaka, JP
Jens Harborth - Carlsbad CA, US
Roger Adami - Carlsbad CA, US
International Classification:
A61K 31/713
A61K 9/00
A61K 9/127
A61P 31/14
Abstract:
This invention provides methods and compositions for inhibiting Ebola virus and Ebola infection utilizing gene silencing siRNAs. The siRNAs can be targeted to one or more Ebola genes including NP, VP30, VP35, L polymerase, glycoprotein (GP), VP24, VP40, and intergenic overlapping regions selected from NP/VP35, VP35/VP40, GP/VP30, and VP24/L. A composition containing the siRNAs can be administered in a delivery vehicle such as liposomes.

Rna Interference Agents For P21 Gene Modulation

View page
US Patent:
20170298086, Oct 19, 2017
Filed:
Jun 27, 2017
Appl. No.:
15/634771
Inventors:
- Osaka, JP
Jens Harborth - Carlsbad CA, US
Cima Cina - San Diego CA, US
Kwok Yin Tsang - Irvine CA, US
Wenbin Ying - San Diego CA, US
Hirokazu Takahashi - Osaka, JP
International Classification:
C07F 9/6533
G01N 33/58
C12Q 1/02
C12N 15/113
C12N 15/113
Abstract:
This invention provides compounds, compositions and methods for modulating the expression of human p21 using RNA interference. The RNA interference molecules can be used in methods for preventing or treating diseases such as malignant tumor. Provided are a range of siRNA structures, having one or more nucleotides being modified or chemically-modified. Advantageous structures include siRNAs with 2′-deoxy nucleotides located in the seed region, as well as other nucleotide modifications.

Sirna Structures For High Activity And Reduced Off Target

View page
US Patent:
20170166898, Jun 15, 2017
Filed:
Dec 12, 2016
Appl. No.:
15/376633
Inventors:
- Osaka, JP
Jens Harborth - Carlsbad CA, US
Cima Cina - San Diego CA, US
Wenbin Ying - San Diego CA, US
Jane Zheng - Oceanside CA, US
Narendra Vaish - Kirkland WA, US
International Classification:
C12N 15/113
Abstract:
This invention provides compounds, compositions and methods for modulating the expression of target genes using RNA interference. RNAi structures and molecules of this invention can be used for modulating or silencing the expression of genes, with high levels of RNAi activity and reduced off target actions. Advantageous structures include siRNAs targeted to any gene having one or more 2′-deoxy nucleotides located in the seed region. The RNA interference molecules can be used in methods for preventing or treating diseases.
Control profile
Jens Harborth from San Diego, CA, age ~60 Get Report